真性红细胞增多症：多发性骨髓瘤的一种罕见表现。
Polycythaemia: an unusual presentation of multiple myeloma.
作者信息
Hutchison Elaine J, Taverna Josephine A, Yu Qi, Yeager Andrew M
机构信息
Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA.
Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, USA University of Arizona Cancer Center, Tucson, Arizona, USA.
出版信息
BMJ Case Rep. 2016 Sep 20;2016:bcr2016216686. doi: 10.1136/bcr-2016-216686.
Abstract
In contrast to anaemia, polycythaemia is a distinctly uncommon finding in patients with multiple myeloma. We describe the presence of otherwise unexplained polycythaemia in a 57-year-old Caucasian man who was found to have IgG κ multiple myeloma. After treatment of myeloma, the polycythaemia resolved. We reviewed previous reports of polycythaemia associated with multiple myeloma and discuss potential pathophysiological mechanisms that link these 2 conditions.
摘要
与贫血相反，真性红细胞增多症在多发性骨髓瘤患者中是一种明显不常见的表现。我们描述了一名57岁白种男性患者存在无法解释的真性红细胞增多症，该患者被诊断为IgG κ型多发性骨髓瘤。骨髓瘤治疗后，真性红细胞增多症得到缓解。我们回顾了既往关于多发性骨髓瘤相关真性红细胞增多症的报道，并讨论了将这两种情况联系起来的潜在病理生理机制。
相似文献
1
Polycythaemia: an unusual presentation of multiple myeloma.
BMJ Case Rep. 2016 Sep 20;2016:bcr2016216686. doi: 10.1136/bcr-2016-216686.
2
Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.
BMC Nephrol. 2017 Apr 6;18(1):127. doi: 10.1186/s12882-017-0524-7.
3
Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Br J Haematol. 2017 May;177(3):495-497. doi: 10.1111/bjh.14086. Epub 2016 Apr 8.
4
[Cellulitis due to Achromobacter xylosoxidans during bortezomib therapy for multiple myeloma].
Rinsho Ketsueki. 2016 Feb;57(2):175-9. doi: 10.11406/rinketsu.57.175.
5
Bortezomib: Potential Key Role in the Treatment of Multiple Myeloma-Related Acquired Hemophilia A.
Semin Thromb Hemost. 2017 Feb;43(1):109-112. doi: 10.1055/s-0036-1597648. Epub 2016 Dec 19.
6
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
J Med Case Rep. 2018 Feb 18;12(1):40. doi: 10.1186/s13256-017-1550-6.
7
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20.
8
Bortezomib improves survival in rare myeloma.
Lancet Oncol. 2016 Jun;17(6):e227. doi: 10.1016/S1470-2045(16)30129-2. Epub 2016 May 6.
9
The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.
Haematologica. 2018 Jul;103(7):e311-e314. doi: 10.3324/haematol.2017.184754. Epub 2018 Mar 15.
10
Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
Retin Cases Brief Rep. 2014 Fall;8(4):348-51. doi: 10.1097/ICB.0000000000000067.
引用本文的文献
1
Secondary Polycythemia May Be an Early Clinical Manifestation of Multiple Myeloma: A Case Report.
J Blood Med. 2024 Jul 29;15:325-330. doi: 10.2147/JBM.S465827. eCollection 2024.
2
A Rare Coexistence of Multiple Myeloma and Polycythemia Vera.
J Hematol. 2023 Oct;12(5):227-230. doi: 10.14740/jh1167. Epub 2023 Oct 21.
3
Concurrent Polycythemia Vera with Newly Diagnosed Multiple Myeloma: Case Report and Literature Review.
J Inflamm Res. 2023 Sep 18;16:4117-4121. doi: 10.2147/JIR.S428977. eCollection 2023.
4
TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis.
Front Endocrinol (Lausanne). 2022 May 19;13:886961. doi: 10.3389/fendo.2022.886961. eCollection 2022.
5
Multiple myeloma and primary erythrocytosis in a dog.
Can Vet J. 2021 Aug;62(8):849-853.
6
Polycythaemia following treatment of lymphoplasmacytic lymphoma.
BMJ Case Rep. 2020 Oct 30;13(10):e235687. doi: 10.1136/bcr-2020-235687.
7
Concurrent Polycythemia of Undetermined Etiology and Smouldering Plasma Cell Myeloma.
Case Rep Pathol. 2018 Sep 16;2018:8781721. doi: 10.1155/2018/8781721. eCollection 2018.
本文引用的文献
1
Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation.
Leukemia. 2015 Dec;29(12):2414-6. doi: 10.1038/leu.2015.298. Epub 2015 Oct 26.
2
A new case of TEMPI syndrome.
Clin Kidney J. 2012 Dec;5(6):556-8. doi: 10.1093/ckj/sfs139. Epub 2012 Nov 1.
3
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
4
Subcutaneous bortezomib for treatment of TEMPI syndrome.
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e221-3. doi: 10.1016/j.clml.2014.07.004. Epub 2014 Jul 15.
5
Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):31-6. doi: 10.1016/j.clml.2013.09.015. Epub 2013 Sep 30.
6
Bortezomib to treat the TEMPI syndrome.
N Engl J Med. 2012 May 10;366(19):1843-5. doi: 10.1056/NEJMc1202649.
7
The TEMPI syndrome--a novel multisystem disease.
N Engl J Med. 2011 Aug 4;365(5):475-7. doi: 10.1056/NEJMc1106670.
8
Perirenal fluid collections and monoclonal gammopathy.
Nephrol Dial Transplant. 2012 Jan;27(1):448-9. doi: 10.1093/ndt/gfr433. Epub 2011 Aug 2.
9
JAK2 mutation-negative secondary erythrocytosis in smoldering plasma cell myeloma: a case study and review of the literature.
Acta Haematol. 2011;126(3):169-71. doi: 10.1159/000328996. Epub 2011 Jul 27.
10
Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure.
N Engl J Med. 2010 Jul 29;363(5):463-75. doi: 10.1056/NEJMcpc1004086.
Zotero 插件